4
ALL4
ElutiaYear
4
ALL4
2023DEALS // DEV.
4
ALL3
Deals1
DevelopmentsCountry
4
ALL4
U.S.A4
ALL2
Berkeley Biologics1
HighCape Capital1
Not ApplicableTherapeutic Area
4
ALL4
Infections and Infectious DiseasesStudy Phase
4
ALL4
PreclinicalDeal Type
3
ALL2
Divestment1
Private PlacementProduct Type
4
ALL4
Small moleculeDosage Form
4
ALL4
ImplantLead Product
4
ALL4
RifampicinTarget
0
ALLLead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million
Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...
Brand Name : CanGaroo RM
Molecule Type : Small molecule
Upfront Cash : $35.0 million
November 09, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : HighCape Capital
Deal Size : $26.2 million
Deal Type : Private Placement
Elutia Announces Private Placement for Proceeds up to $26 Million
Details : The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Brand Name : CanGaroo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : HighCape Capital
Deal Size : $26.2 million
Deal Type : Private Placement
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million
Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...
Brand Name : CanGaroo
Molecule Type : Small molecule
Upfront Cash : $35.0 million
September 18, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial Envelope
Details : CanGaroo RM Antibacterial Envelope contains the antibiotics rifampin and minocycline, which have been shown in preclinical testing to reduce bacterial colonization on the envelope.
Brand Name : CanGaroo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?